





Enhancing local medicine 
production in east and
southern Africa
This brief outlines the factors that affect medicines production in East and 
Southern Africa, drawing on the African Union, Southern Africa Development 
Community (SADC) and East African Community (EAC) pharmaceutical plans. 
It identifies the barriers to local production as: lack of supportive policies, capital 
and skills constraints, gaps in regulatory framework, small market size and 
weak research and development capacities. It highlights, from case study work 
in selected countries in East and Southern Africa the potential opportunities for 
strengthening local medicine production. In the brief we propose that African 
countries strengthen domestic capacities, co-operation between domestic private 
and public sectors within ESA countries, and regional co-operation across ESA 
countries to address bottlenecks. Some areas such as infrastructure development 
and training may be important groundwork for others, such as technology 
transfer and research and development. South-south cooperation in medicines 
production can play a role in this but it cannot be assumed. Negotiations on 
south-south arrangements should look not only at the immediate production 
investment, but at strengthening capacities for research and development, 
for regulation, medicines price and quality monitoring, prequalification, 
infrastructure and human resource development.
Medicines production in 
east and southern Africa
Few countries in east and southern Africa 
have a domestic pharmaceutical industry. As
shown in the chart below, only South Africa 
and Kenya have a larger number of domestic
manufacturing plants. Kenya exports 
between 35 and 45 percent of its 
pharmaceuticals, particularly to other east, 
central and southern Africa countries.
Thirty seven sub-Saharan African countries 
have some pharmaceutical production, 
mainly for formulation of finished dosage 
forms, although in twenty five countries this 
is limited to packaging or labeling. 
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Number of domestic pharmaceutical manufacturers in the ESA region 
Sources: WHO (2011), EAC (2011)
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Only South Africa has a limited degree of 
Active Pharmaceutical Ingredient (API) 
production. Most production outside 
South Africa consists of non-complex, 
high volume essential products, such 
as basic analgesics, simple antibiotics, 
anti-malarial drugs and vitamins. As a 
result, Africa has 14 percent of the world’s 
population but produces only  
3 percent of the world’s medicines and 
its pharmaceutical manufacturing sector 
contributes only 25-30 percent of the 
continent’s needs (IFC 2008).
Barriers to local 
production
This gap in domestic manufacturing 
has been identified as a concern in the 
continent. The African Union (AU) Summit 
adopted a Pharmaceutical Manufacturing 
Plan for Africa in 2007. The plan calls for 
a mapping of productive capacities on 
the continent to inform a manufacturing 
agenda. It identifies the barriers and 
bottlenecks to domestic medicine 
production, as do the subsequent 2007-
2016 SADC and 2012-2016 East African 
Community (EAC) plans. All the plans 
have noted the over reliance on imports 
of medicines from developed countries. 
From these plans and our own work we 
identify the barriers to expanding medicine 
production in the region as:
• Weak policy implementation and 
limited government support in the 
initial stages to encourage domestic 
investment in the industry;
• Small national markets, making 
it difficult for local manufacturers 
to achieve economies of scale in 
production;
• Importation of most active 
pharmaceutical ingredients and 
medicines, offering little value addition 
in local production, weakening 
technology transfer and making the 
supply chain vulnerable to corruption;
• High tariffs on imported inputs, high 
interests rates on credit, together with 
ageing and unreliable energy, water 
and transport infrastructure;
• Shortfalls in capital and technology, 
and dependence on external funding;
• Shortfalls in skills, scientists and 
industrial pharmacists and in 
laboratories;
• Limited international linkages and 
mechanisms for and intellectual 
property constraints in technology 
transfer and in the sourcing of active 
pharmaceutical ingredients;
• A prohibitive intellectual property 
regime;
• Gaps in the regulatory framework and 
in enforcement capacities to ensure 
quality assured, safe and efficacious 
medicines; and
• Weak or non-existent capacities for 
research and development.
These barriers interact as shown in the 
flow chart below.
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Transaction and Information costs,
including those related to knowledge
of local markets, cultures and
conditions
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Addressing these interacting barriers 
thus needs a multifaceted approach. 
For example, even where there is 
willingness to transfer know-how or 
technology, recipients must also have the 
capacities to effectively appropriate the 
technology transferred, in a policy and 
political environment that is conducive to 
pharmaceutical innovation.
Overcoming barriers to 
local production
Exploring the experience of countries 
like Uganda that have strengthened a 
local producer through a south –south 
partnership; and of countries like 
Zimbabwe and Kenya that have strong 
domestic production capacities points to 
measures that have already been taken 
in the region to strengthen domestic 
production of medicines, including:
• Governments setting an enabling 
regulatory environment, with sound 
laws governing the pharmaceutical 
sector, with a capacity for their 
enforcement, including laboratories 
and personnel;
• Local training and research and 
development institutions that 
develop capacities for science and 
technology to sustain a domestic 
industry;
• Regional trade agreements to widen 
the market size to improve the returns 
to producers, and to access skills, 
technology and investment capital;
While many countries have national 
pharmaceutical policies, there is a gap 
between policy and implementation 
in a number of areas. For example 
governments could introduce stronger 
measures to exempt duty and value added 
tax (VAT) on imported pharmaceutical 
raw materials and packaging materials to 
stimulate local production, together with 
reduced corporate tax rates, investment 
tax credits and other incentives for 
companies to set up production. Where 
countries have done the opposite, 
exempting imported drugs from duties and 
taxes, while raising them on raw materials 
and packaging, this makes imports 
cheaper than locally produced medicines. 
These contradictory measures arise if 
there is a gap in the dialogue between 
governments, pharmaceutical companies 
and training institutions on what capacities 
and measures are needed to support the 
local pharmaceutical industry.
The role of regional 
and south–south co-
operation 
There is evidence of new interest in 
medicines markets and production in east 
and southern Africa, with India, Brazil, 
Thailand, China and other emergent 
economies becoming involved. In 
Uganda, for example, on request by the 
government, Cipla Ltd, a leading Indian 
pharmaceutical manufacturer entered a 
joint venture with local partner Quality 
Chemicals Ltd (QCL). This enabled local 
production of antiretroviral medicines and 
anti-malarials under licence from Cipla 
Ltd. Evidence of south-south co-operation 
was also found in the ESA region in 
the establishment of a research and 
development division at the QCIL plant 
with the help of Cipla Limited, in training 
and exchange programmes; and in co-
operation around human resources for 
health with China, Cuba, Brazil and India.
However south-south co-operation 
cannot be assumed to imply equality in 
partnership. Emergent economies outside 
the region have interests in consolidating 
their own trade position and African 
countries would need to negotiate for 
their specific interests in south-south 
co-operation. It may be that co-operation 
on building capacities and infrastructure 
in the region facilitates future investment 
in manufacture in the longer term more 
than direct partnerships in pharmaceutical 
manufacturing.
ESA countries could, as a more primary 
goal, strengthen domestic strategies, 
capacities and co-operation between 
domestic private and public sectors within 
ESA countries, and regional co-operation 
across ESA countries to address 
bottlenecks. Regional co-operation is 
also important to harmonise medicine 
regulation and for medicine procurement. 
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In the Southern African Development 
Community (SADC) region, there are 
government-to-government agreements 
on recruitment of pharmacists; bilateral 
agreements offering preferential 
treatment and flexibility for medicines 
markets; co-operation and specialist 
exchanges on specific health services 
and telemedicine; and co-operation on 
areas of training of health personnel. 
ESA country membership of the Common 
Market for Eastern and Southern 
(COMESA), SADC and the East African 
Community (EAC) offers opportunities 
to negotiate for a tripartite Free Trade 
Area between the three blocs to widen 
markets for medicines and to strengthen 
regional interactions on the technology, 
infrastructure, capacities, research and 
development and capital needed for 
pharmaceutical production.
Areas of action for 
enhancing local 
production 
Our research suggests a need for 
immediate and medium term actions to
1. Strengthen awareness, oversight and 
reporting on implementation of laws, 
policies and co-operation agreements 
on pharmaceutical production, 
including to ensure transparency and 
quality of practice;
2. Establish dialogue among 
governments, pharmaceutical 
companies and training institutions 
on human resource requirements 
projected for the industry at national 
and regional level; on measures for 
legal recognition of pharmaceutical 
specialties (clinical, industrial 
pharmacists, laboratory technicians, 
scientist and engineers) and 
designing and implementing schemes 
to train, attract and retain personnel;
3. Implement agreed infrastructure 
projects in water, energy and transport 
corridors under regional integration 
programmes in the EAC and SADC 
regions;
4. Stimulate and support local 
pharmaceutical industries through 
fiscal incentives and through tax and 
duty exemptions on imported inputs to 
local production;
5. Develop through ministries of trade 
and health a database on essential 
medicines, and their local production 
or imported source and cost, to inform 
procurement and investment; and to
6. Negotiate for a share of external funds 
to be used for local procurement from 
companies prequalified by the World 
Health Organisation.
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